Lerato Mohapi to Longitudinal Studies
This is a "connection" page, showing publications Lerato Mohapi has written about Longitudinal Studies.
Connection Strength
0,048
-
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015 Jul; 15(7):793-802.
Score: 0,028
-
Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS. 2010 Nov 13; 24(17):2687-96.
Score: 0,020